FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| Washington, | D.C. | 20549 |
|----------------|------|-------|
| vvasiliigtoii, | D.C. | 20049 |

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

| OMB APPROVAL | | | | | | | | | | |
|--------------------------|-----------|--|--|--|--|--|--|--|--|--|
| | | | | | | | | | | |
| OMB Number: | 3235-0287 | | | | | | | | | |
| Estimated average burden | | | | | | | | | | |
| hours per response. | 0.5 | | | | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person* Landis John B. | | | | | 2. Issuer Name and Ticker or Trading Symbol EyePoint Pharmaceuticals, Inc. [EYPT] | | | | | | | | Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner | | | | | |
|--|---|---|---|--|---|---|--------------|--|---|---|---|---|---|---|--|--|---------------------------------------|--|
| (First) (Middle) EYEPOINT PHARMACEUTICALS, INC. | | | | 01/ | 3. Date of Earliest Transaction (Month/Day/Year) 01/05/2024 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | | below) below) 6. Individual or Joint/Group Filing (Check Applicable | | | | | |
| 480 PLEASANT STREET (Street) | | | | - | | | | | | | | | X Form filed by One Reporting Person Form filed by More than One Reporting | | | | | |
| VATERTOWN MA 02472 | | | | Rı | Rule 10b5-1(c) Transaction Indication | | | | | | | | | | | | | |
| (5 | State) | (Zip) | | Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intensatisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | | | | | | | | at is intended | to | | | | | |
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | | | | | | | | | | |
| Date | | | | ay/Year) Execution | | ecution Date, ny | | Transaction Disposed Of (I Code (Instr. 5) | | ies Acquired (A) or Of (D) (Instr. 3, 4 and | | 5. Amount of Securities Beneficially Owned Following | | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | | 7. Nature of Indirect Beneficial Ownership | | |
| | | | | | | | | Code V | | Amount | (A) or (D) | Price | Transact | Reported Transaction(s) (Instr. 3 and 4) | | (| Instr. 4) | |
| Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | | | |
| 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | if any | ate, Transact | | | on of Derivati Securiti Acquire (A) or Dispose of (D) (Ii | | Expiration Date | | of Securities Underlying Derivative Securities | | es J Security | 8. Price of Derivative Security (Instr. 5) | derivative Securities Beneficially Owned Following Reported | ily | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | Beneficial Ownership (Instr. 4) | |
| | | | | Code | v | (A) | (D) | Date Exercisable | | | Title | Amount or Number of Shares | | | | | | |
| \$0.00 | 01/05/2024 | | | A | | 10,000 | | 01/05/2025 | 01 | /04/2034 | Common Stock | 10,000 | \$0.00 | 10,000 |) | D | | |
| \$20.4 | 01/05/2024 | | | A | | 20,000 | | 01/05/2025 | 01 | /04/2034 | Common Stock | 20,000 | \$0.00 | 20,000 |) | D | | |
| \$20.4 | 01/05/2024 | | | A | | 25,014 | | 01/05/2025 | 01 | /04/2034 | Common Stock | 25,014 | \$0.00 | 25,014 | 4 | D | | |
| | John B. (FEPOINT PI ASANT ST FOWN M (SE Conversion or Exercise Price of Derivative Security \$0.00 | John B. (First) EPOINT PHARMACEUTIC ASANT STREET FOWN MA (State) Tab Security (Instr. 3) 2. Conversion or Exercise Price of Date (Month/Day/Year) Derivative Security \$0.00 01/05/2024 \$20.4 01/05/2024 | John B. (First) (Middle) EPOINT PHARMACEUTICALS, INCASANT STREET FOWN MA 02472 (State) (Zip) Table II - Non Security (Instr. 3) Table II - I ((Month/Day/Year) If any (Month/Day) Security \$0.00 01/05/2024 \$20.4 01/05/2024 | Conversion or Exercise Price of Derivative Security Security | Security (Instr. 3) Security (Instr. 3) | EyePoint Pharmaceuticals, Inc. Asant Street | EyePoint Ph. | EyePoint Pharm | Security (Instr. 3) Security (Instr. 3) | Security (Instr. 3) Security (Instr. 3) | EyePoint Pharmaceuticals, Inc. Sant Street | EyePoint Pharmaceuticals, Inc. [EYPT] | Check this box to indicate that a transaction was made pursuant to a control satisfy the affirmative defense conditions of Rule 1005-1(c). See Instruction (Month/Day/Year) | Security (Instr. 3) Security (Instr. 3) | EyePoint Pharmaceuticals, Inc. EyePT | EyePoint Pharmaceuticals, Inc. EyePT Surface Conversion Conv | EyePoint Pharmaceuticals, Inc. EYPT | |

Explanation of Responses:

Remarks:

/s/ Ron Honig, Attorney-in-Fact 01/09/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $^{^{\}star}$ If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).